AnalyzeDirect Chowdhury S, Dominguez I, Sharratt E, Spernyak J, Brattain MG, Ashwani R. Anti-tumor activity of the IGF-1R kinase inhibitor PQIP in colon cancer. Clin Exp Pharmacol. June 2013;S4(005).
Full Text – Open Access
Publication Date
June 2013
How Analyze was Used
“Tumor volumes were calculated by manually drawing regions of interest (ROI’s) over the tumors and calculating volumes in commercially available medical imaging processing software (Analyze 7.0, AnalyzeDirect, Overland Park, KS).”
Keywords
Apoptosis
Colonic Neoplasms
Insulin Growth Factor II
Mice
PQIP
Receptor, IGF, Type 1
Xenograft Model Antitumor Assays
Author Affiliation(s)
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198-7696, US. (SC, MGB)
Department of Surgery, State University of New York at Buffalo, Buffalo, NY 14203, US. (ID)
Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, US. (ES)
Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, US. (JS)
Division of Surgical Oncology, Department of Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, US. (AR)
ID# 245
Tags: Apoptosis, Colonic Neoplasms, IGF Type 1 Receptor, Insulin Growth Factor II, Mice, PQIP, Xenograft Model Antitumor Assays